ReviewClinical microbiology reviews2005
Immune responses and disease enhancement during respiratory syncytial virus infection.
Review in Clinical microbiology reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 1 synthesis or guideline pooled it, 289 citations in OpenAlex.
- Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children.The European respiratory journal · 2022Pooled it
- Viral load drives disease in humans experimentally infected with respiratory syncytial virus.American journal of respiratory and critical care medicine · 2010Trial
- Article
- Review
- Review
- Rational design 2.0: transitioning from static structural biology to computational prioritization and iterative vaccine optimization for RSV.Frontiers in immunology · 2026Review
- Double Trouble: The First Reported Case of Evans Syndrome Following RSV Vaccination.Hematology reports · 2025Article
- Article
- Differential NF-κB mRNA Expression in Blood and Buccal Mucosa of Pediatric Patients with RSV Bronchiolitis.Genes · 2025Article
- Enhanced Pathogenic Consequences Induced by a Seven-Amino-Acid Extension in the G Protein of the HRSV BA9 Genotype.International journal of molecular sciences · 2025Article
- Article
- Exposure to bacterial PAMPs before RSV infection exacerbates innate inflammation and disease via IL-1α and TNF-α.Mucosal immunology · 2024Article
- From Pancytopenia to Hyperleukocytosis, an Unexpected Presentation of Immune Reconstitution Inflammatory Syndrome in an Infant with Methylmalonic Acidemia.Children (Basel, Switzerland) · 2024Article
- Early-life pulmonary viral infection leads to long-term functional and lower airway structural changes in the lungs.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.Clinical and experimental immunology · 2023Review
- Respiratory syncytial virus infection and novel interventions.Nature reviews. Microbiology · 2023Review
- Article
- Binding of respiratory syncytial virus particles to platelets does not result in their degranulationAccess microbiology · 2023Article
- A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Neonatal Immune Responses to Respiratory Viruses.Frontiers in immunology · 2022Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is one of the commonest and most troublesome viruses of infancy. It causes most cases of bronchiolitis, which is associated with wheezing in later childhood. In primary infection, the peak of disease typically coincides with the development of specific T- and B-cell responses, which seem, in large part, to be responsible for disease. Animal models clearly show that a range of immune responses can enhance disease severity, particularly after vaccination with formalin-inactivated RSV. Prior immune sensitization leads to exuberant chemokine production, an excessive cellular influx, and an overabundance of cytokines during RSV challenge. Under different circumstances, specific mediators and T-cell subsets and antibody-antigen immune complex deposition are incriminated as major factors in disease. Animal models of immune enhancement permit a deep understanding of the role of specific immune responses in RSV disease, assist in vaccine design, and indicate which immunomodulatory therapy might be beneficial to children with bronchiolitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.